Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers
- Conditions
- Peripheral Artery DiseaseIschaemic Ulcer of Lower Leg Due to Atherosclerotic DiseaseChronic Limb Threatening IschemiaIschemic Ulcer of Foot
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04267640
- Locations
- 🇺🇸
ILD Research Center, Carlsbad, California, United States
🇺🇸Rancho Research Institute, Downey, California, United States
🇺🇸Limb Preservation Platform, Inc., Fresno, California, United States
A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia
- Conditions
- Critical Limb Ischemia
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02974179
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia
- Conditions
- Critical Limb Ischemia
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02144610
- Locations
- 🇺🇸
Carondelet Heart and Vascular Institute, Tucson, Arizona, United States
🇺🇸Central Arkansas Veteran's Healthcare System, Little Rock, Arkansas, United States
🇺🇸University of California, San Diego (UCSD), La Jolla, California, United States
A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
- Conditions
- Peripheral Arterial DiseaseVascular DiseasesCritical Limb Ischemia
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02016755
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers
- Conditions
- Arterial Occlusive DiseasePeripheral Vascular DiseaseIschemiaUlcers
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- AnGes USA, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00189540
- Locations
- 🇺🇸
Baptist Clinical Research, Pensacola, Florida, United States
🇺🇸The Care Group, LLC, Indianapolis, Indiana, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next